TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05720624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anhydrous Enol-oxaloacetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anhydrous Enol-oxaloacetate
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of CSF and blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of CSF and blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of CSF and blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of CSF and blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRS imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRS imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRS imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRS imaging
Study: NCT05261750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Auto-Dendritic Adjuvant Therapy
Description: Treatment with standard medical therapy (radiotherapy or chemoradiation) and auto-dendritic adjuvant therapy via intramuscular 3 times injection every 1 week.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allo-Dendritic-Secretome Adjuvant Therapy
Description: Treatment with standard medical therapy (radiotherapy or chemoradiation) and allo-dendritic-secretome adjuvant therapy 2 cc 1 times injection, and then followed by auto-dendritic therapy via intramuscular 3 times injection every 1 week.
Study: NCT05720624

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06656741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resting State
Description: Resting state is a mental state and a research paradigm that people do nothing and idle as much as possible to show their baseline neuro signals. In this task, we instructed participants to rest with their eyes opened for 6 minutes. The VR environment of blue sky and swaying meadow was presented to the participants throughout this task.
Study: NCT05720624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06656741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Breathing
Description: Mindful breathing is a state that people focus on their inner sensation. In this task, the meadow's motion in the VR environment corresponded to the participants' inhalation and exhalation, as detected by the respiration belt. The participants were instructed to focus mentally on their bodily sensations as they breathed, with the meadow's sway as a visual cue.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Breathing
Description: Guided breathing refers to the breath training technique that trainees are guided to inhale and exhale according to a fixed tempo. In this task, meadow swayed in a fixed tempo of 4 seconds back and 6 seconds forth. The participants were instructed to synchronize their inhalation with the meadow's backward motion (lasting 4 seconds) and their exhalation with its forward motion (lasting 6 seconds).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Counting
Description: Breath counting refers to the breath training technique that trainees mentally count the numbers of breath cycles they have finished in a certain period of time. In this task, similar to the mindful breathing task, the meadow's motion was synchronized with the participants' breathing patterns. During the 6 minutes, we instructed the participants to breathe naturally and mentally count their breathing cycles.
Study: NCT06604325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: All women recruited to Group A will receive tranexamic acid 1 gram in 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All women recruited to Group B will receive 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
Study: NCT04631562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1820 IV
Description: ALXN1820 IV (450 mg) will be administered as an IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Placebo IV will be administered as an IV infusion.
Study: NCT05457985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Primary Care (PE-PC)
Description: Treatment follows the standardized PE-PC manual and workbook.PE-PC consists of four weekly 30-minute sessions. In vivo and imaginal exposure are introduced at the first session and reviewed at Sessions 2-4. To conduct in vivo exposure, participants repeatedly and systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Primary Care (PE-PC)
Description: Treatment follows the standardized PE-PC manual and workbook.PE-PC consists of four weekly 30-minute sessions. In vivo and imaginal exposure are introduced at the first session and reviewed at Sessions 2-4. To conduct in vivo exposure, participants repeatedly and systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Primary Care (PE-PC)
Description: Treatment follows the standardized PE-PC manual and workbook.PE-PC consists of four weekly 30-minute sessions. In vivo and imaginal exposure are introduced at the first session and reviewed at Sessions 2-4. To conduct in vivo exposure, participants repeatedly and systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Prolonged Exposure
Description: Treatment will follow the standardized PE manual. Participants will have 60 minute sessions once a week for eight weeks During these sessions, participants will practice in vivo, imaginal, and emotional exposure as well as continue these exposure exercises every day at home.
Study: NCT05782855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Robot assisted physical training during acute hospitalisation
Description: Active training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the exercise movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform extension of hip and knee. The patient must use their muscular power to stretch the leg while ROBERT® provides resistance.~Training is defined as a minimum of three sessions before discharge.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Passive Robot assisted physical training during acute hospitalisation
Description: Passive training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform passive extension of hip and knee. ROBERT® moves the leg independently without the patient using any muscle power.~Training is defined as a minimum of three sessions before discharge.
Study: NCT06283706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tryptophan
Description: There are 7 different tryptophan test levels ranging from 0.5, 2, 4, 6, 8, 10, 12 mg.kg-1.day.1
Study: NCT06670482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Description: Delivery of positive airway pressure to the lungs via an interface, such as a mask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Description: Delivery of positive airway pressure to the lungs via an interface, such as a mask.
Study: NCT05457985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Prolonged Exposure
Description: Treatment will follow the standardized PE manual. Participants will have 60 minute sessions once a week for eight weeks During these sessions, participants will practice in vivo, imaginal, and emotional exposure as well as continue these exposure exercises every day at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Supported PTSD Coach App
Description: This is a brief psychotherapy that uses the PTSD Coach mobile app developed by the study team. The PTSD Coach app incorporates evidence-based assessment, psychoeducation, and cognitive behavioral therapy and self-management strategies that are customizable to the user.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Supported PTSD Coach App
Description: This is a brief psychotherapy that uses the PTSD Coach mobile app developed by the study team. The PTSD Coach app incorporates evidence-based assessment, psychoeducation, and cognitive behavioral therapy and self-management strategies that are customizable to the user.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Supported PTSD Coach App
Description: This is a brief psychotherapy that uses the PTSD Coach mobile app developed by the study team. The PTSD Coach app incorporates evidence-based assessment, psychoeducation, and cognitive behavioral therapy and self-management strategies that are customizable to the user.
Study: NCT04134910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
Study: NCT06648850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-001
Description: Phenyephrine + Alpha 1 Agonist (GRAS) + TAAR Agonist (GRAS) Topical Solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Topical Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine Topical Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intact5
Description: Cosmetic formulation containing bitter orange extract
Study: NCT06181422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: lactoferrin 100 mg
Study: NCT04711057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based PA program
Description: After completing the PR program, the experimental group (EG) will enroll in a 6-month personalized community-based PA program, which should be attended twice-weekly, minimum. During the first month the physiotherapist will guide patients through all available physical activities; afterwards, patients will be asked to choose one or two activities, according to their preference, which they'll attend for five more months. Physiotherapists' support will gradually decrease over time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Exercise training, twice a week, and education and psychosocial support once every other week during 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Exercise training, twice a week, and education and psychosocial support once every other week during 12 weeks.
Study: NCT04699630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1402
Description: All subjects will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 of every 3 weeks. One cycle is defined as 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1402
Description: All subjects will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 of every 3 weeks. One cycle is defined as 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1402
Description: All subjects will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 of every 3 weeks. One cycle is defined as 3 weeks.
Study: NCT06356558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention (VISACT)
Description: The intervention is an implementation strategy called VISACT: VISuAl aids, Coach providers in communication, and Train organizations in health literacy. This strategy will be delivered to patients, providers, and organizations through a novel interactive response platform.
Study: NCT06670482

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Description: Delivery of positive airway pressure to the lungs via an interface, such as a mask.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Description: Delivery of positive airway pressure to the lungs via an interface, such as a mask.
Study: NCT06618313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCXH-213,an mRNA-LNP based in vivo CAR therapy
Description: JCXH-213 infusion
Study: NCT06495710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure treatment algorithm
Description: Single or combination antihypertensive therapy as needed: 1) amlodipine (2.5-10 mg), 2) telmisartan (20-80 mg) or losartan (25-100 mg), 3) chlorthalidone (6.25-25 mg), or 4) spironolactone (12.5-50 mg). a two-drug regimen with either amlodipine + chlorthalidone or telmisartan + chlorthalidone will be initiated following randomization. If a diuretic is contraindicated, amlodipine + telmisartan will be initiated. For those over 75 years, either amlodipine or telmisartan will be initiated at baseline if SBP is \<140 mmHg. In the standard treatment group (SBP goal of \< 140 mmHg), participants will either be prescribed amlodipine or telmisartan/losartan as initial therapy. If \>3 medications are necessary to reach the intensive goal and no first line options remain, potassium sparing diuretics or direct vasodilators will be considered.
Study: NCT04948476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Dialysis and Structured Discontinuation (S2D2)
Description: Prescription to minimize dialysis-induced ischemia~* Cool dialysate (35.0◦C)~* Dialysate sodium of 145mmol/L~* Dialysate calcium of 1.5mmol/L~* Maximum ultrafiltration rate of 10mL/kg/hour (if no weight, maximum is 500mL/hour)~  * Note: If dialysis machines cannot get to the specified values, values closest to these are acceptable.~Structured dialysis discontinuation (all criteria met)~* Most recent pre-dialysis potassium \<6mmo/L and bicarbonate \>12mmol/L~* Most recent urine volume ≥1L/day OR last ultrafiltration on dialysis \<1L/session~* If available, timed urine collection with result for mean creatinine and/or urea clearance \>12mL/min
Study: NCT06495710

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure treatment algorithm
Description: Single or combination antihypertensive therapy as needed: 1) amlodipine (2.5-10 mg), 2) telmisartan (20-80 mg) or losartan (25-100 mg), 3) chlorthalidone (6.25-25 mg), or 4) spironolactone (12.5-50 mg). a two-drug regimen with either amlodipine + chlorthalidone or telmisartan + chlorthalidone will be initiated following randomization. If a diuretic is contraindicated, amlodipine + telmisartan will be initiated. For those over 75 years, either amlodipine or telmisartan will be initiated at baseline if SBP is \<140 mmHg. In the standard treatment group (SBP goal of \< 140 mmHg), participants will either be prescribed amlodipine or telmisartan/losartan as initial therapy. If \>3 medications are necessary to reach the intensive goal and no first line options remain, potassium sparing diuretics or direct vasodilators will be considered.
Study: NCT05847881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided at home activities
Description: After the kick-off meeting participants will complete the cultural probe kit for 3 weeks. This kit is a design research tool, to prompt participants to document, map, journal, and reflect on various aspects of daily lives. Following this, participants will attend a facilitated workshop and then complete the next at-home kits.
Study: NCT04948476

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Dialysis prescription ordered by their clinical team. Decisions on dialysis discontinuation will be left to individual clinicians and will not be guided by a standard protocol.
Study: NCT05515562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Injection
Description: All participants will receive Intravenous (IV) omadacycline
Study: NCT05343390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced implementation package
Description: Individual training with teaching and modeling (tablet-guided, \~8 hours) Small group training with practice and feedback (tablet-guided, \~16 hours) Ongoing continuous quality improvement sessions (tablet-guided, \~2 hours/month)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard implementation package
Description: Individual training with teaching (facilitator-guided, \~2 hours) Small group practice (facilitator-guided, \~1 hour) Ongoing clinic support (facilitator-guided, \~30 minutes/month)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard implementation package
Description: Individual training with teaching (facilitator-guided, \~2 hours) Small group practice (facilitator-guided, \~1 hour) Ongoing clinic support (facilitator-guided, \~30 minutes/month)
Study: NCT05720624

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06143956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC. ISA specific interventions will be listed in the ISA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3841136
Description: Administered SC. ISA specific interventions will be listed in the ISA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3841136
Description: Administered SC. ISA specific interventions will be listed in the ISA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC. ISA specific interventions will be listed in the ISA.
Study: NCT05824676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable Angle LCP Patella Plating System
Description: FDA approved device, 510K number of, K210408. The Variable Angle LCP Patella Plating System is a device that can be formed to a patients specific need with various anchoring points to best fix what is needed for fixation.
Study: NCT06143956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC. ISA specific interventions will be listed in the ISA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC. ISA specific interventions will be listed in the ISA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC. ISA specific interventions will be listed in the ISA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC. ISA specific interventions will be listed in the ISA.
Study: NCT05824676

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional Fixation
Description: Traditional fixation methods for patellar fracture (screws, suture fixation, wire fixation, other plates).
Study: NCT05338580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ271 Injection in Combination with Pembrolizumab
Description: TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
Study: NCT05372939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMT-101 (oral)
Description: AMT 101 is orally administered biological therapeutic taken once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (oral)
Description: Orally administered placebo comparator taken once daily

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Humira (adalimumab)
Description: Humira comparator is administered subcutaneously, on Humira frequency schedule.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Humira (adalimumab)
Description: Humira comparator is administered subcutaneously, on Humira frequency schedule.
Study: NCT04517058

Intervention type: OTHER
Intervention: psychology therapy
Description: If the symptoms are mild, patients will get the psychology therapy. If it's necessary according to patients' willings, patients will be given SSRIs antidepressant therapy.